Kawasaki disease: An evolving paradigm

Autoimmunity Reviews

Volumn 14, Issue 8, 2015, Pages 703-709

  Greco, Antonio ^a   De Virgilio, Armando ^a,b   Rizzo, Maria Ida ^a,b   Tombolini, Mario ^a   Gallo, Andrea ^a   Fusconi, Massimo ^a   Ruoppolo, Giovanni ^a   Pagliuca, Giulio ^a   Martellucci, Salvatore ^a   de Vincentiis, Marco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Aneurysm; Children vasculitis; Coronary arteries; Intravenous immunoglobulins; Kawasaki disease

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; ASPIRIN; IMMUNOGLOBULINS, INTRAVENOUS;

AUTOIMMUNE DISEASE; CLINICAL FEATURE; CORONARY ARTERY; CORONARY ARTERY ANEURYSM; CORONARY ARTERY DILATATION; DIFFERENTIAL DIAGNOSIS; ECHOCARDIOGRAPHY; HISTOPATHOLOGY; HUMAN; IMMUNE DYSREGULATION; LABORATORY TEST; LYMPHADENOPATHY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROGNOSIS; REVIEW; SYSTEMIC VASCULITIS; DIAGNOSIS, DIFFERENTIAL; FEVER; HUMANS; IMMUNOLOGY;

ASPIRIN; DIAGNOSIS, DIFFERENTIAL; FEVER; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROGNOSIS;

EID: 84930757874     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.04.002     Document Type: Review

References (74)

1. Kato H., Sugimura T., Akagi T., Sato N., Hashino K., Maeno Y., et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation 1996, 94:1379-1385.
2. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Allergy 1967, 16:178-222.
3. Newburger J.W., Takahashi M., Gerber M.A., et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004, 114:1708-1733.
4. Harnden A., Takahashi M., Burgner D. Kawasaki disease. BMJ 2009, 338:b1514.
5. Nakamura Y., Yashiro M., Uehara R., Sadakane A., Tsuboi S., Aoyama Y., et al. Epidemiologic features of Kawasaki disease in Japan: results of the 2009-2010 nationwide survey. J Epidemiol 2012, 22:216-221.
6. Park Y.W., Han J.W., Hong Y.M., Ma J.S., Cha S.H., Kwon T.C., et al. Epidemiological features of Kawasaki disease in Korea, 2006-2008. Pediatr Int 2010, 53:36-39.
7. Huang W.C., Huang L.M., Chang I.S., Chang L.Y., Chiang B.L., Chen P.J., et al. Epidemiologic features of Kawasaki disease in Taiwan, 2003-2006. Pediatrics 2009, 123:e401-e405.
8. Holman R.C., Christensen K.Y., Belay E.D., Steiner C.A., Effler P.V., Miyamura J., et al. Racial/ethnic differences in the incidence of Kawasaki syndrome among children in Hawaii. Hawaii Med J 2010, 69:194-197.
9. Uehara R., Yashiro M., Nakamura Y., Yanagawa H. Parents with a history of Kawasaki disease whose child also had the same disease. Pediatr Int 2011, 53:511-514.
10. Onouchi Y., Gunji T., Burns J.C., et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008, 40:35-42.
11. Onouchi Y., Ozaki K., Burns J.C., Shimizu C., Hamada H., Honda T., et al. Common variants in CASP3 confer susceptibility to Kawasaki disease. Hum Mol Genet 2010, 19:2898-2906.
12. Onouchi Y., Ozaki K., Burns J.C., Shimizu C., Terai M., Hamada H., et al. A genome-wide association study identifies three new risk loci for Kawasaki disease. Nat Genet 2012, 44:517-521.
13. Lee Y.C., Kuo H.C., Chang J.S., Chang L.Y., Huang L.M., Chen M.R., et al. Two new susceptibility loci for Kawasaki disease identified through genome-wide association analysis. Nat Genet 2012, 44:522-525.
14. Shimizu C., Jain S., Davila S., Hibberd M.L., Lin K.O., Molkara D., et al. Transforming growth factor-beta signaling pathway in patients with Kawasaki disease. Circ Cardiovasc Genet 2011, 4:16-25.
15. Laird R.M., Laky K., Hayes S.M. Unexpected role for the B cell-specific Src family kinase B lymphoid kinase in the development of IL-17-producing γδ T cells. J Immunol 2010, 185:6518-6527.
16. Sohn M.H., Noh S.Y., Chang W., Shin K.M., Kim D.S., et al. Circulating interleukin 17 is increased in the acute stage of Kawasaki disease. Scand J Rheumatol 2003, 32:364-366.
17. Ikeda K., Yamaguchi K., Tanaka T., Mizuno Y., Hijikata A., Ohara O., et al. Unique activation status of peripheral blood mononuclear cells at acute phase of Kawasaki disease. Clin Exp Immunol 2010, 160:246-255.
18. Wang C.L., Wu Y.T., Liu C.A., Lin M.W., Lee C.J., Huang L.T., et al. Expression of CD40 ligand on CD4{Thorn} T-cells and platelets correlated to the coronary artery lesion and disease progress in Kawasaki disease. Pediatrics 2003, 111:E140-E147.
19. Khor C.C., Davila S., Breunis W.B., Lee Y.C., Shimizu C., Wright V.J., et al. Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Nat Genet 2011, 43:1241-1246.
20. Suzuki H., Terai M., Hamada H., Honda T., Suenaga T., Takeuchi T., et al. Cyclosporin a treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011, 30:871-876.
21. Tremoulet A.H., Pancoast P., Franco A., Bujold M., Shimizu C., Onouchi Y., et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012, 161:506-512.
22. Burns J.C., Herzog L., Fabri O., Tremoulet A.H., Rodó X., Uehara R., et al. Seasonality of Kawasaki disease: a global perspective. PLoS One 2013, 8:e74529.
23. Uehara R., Belay E.D. Epidemiology of Kawasaki disease in Asia, Europe, and the United States. J Epidemiol 2012, 22:79-85.
24. Yaganawa H., Yashiro M., Nakamura Y., Hirose K., Kawasaki T. Nationwide surveillance of Kawasaki disease in Japan. Pediatr Infect Dis J 1995, 14:69-71.
25. Nomura Y., Yoshinaga M., Masuda K., Takei S., Miyata K. Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6months of age from developing Kawasaki syndrome. J Infect Dis 2002, 185:1677-1680.
26. Burgner D., Harnden A. Kawasaki disease: what is the epidemiology telling us about the etiology?. Int J Infect Dis 2005, 9:185-194.
27. Rowley A. Kawasaki disease: novel insights into etiology and genetic susceptibility. Annu Rev Med 2011, 62:69-77.
28. Saeki Y., Ishihara K. Infection-immunity liaison: pathogen-driven autoimmune-mimicry (PDAIM). Autoimmun Rev 2014, 13:1064-1069.
29. Meissner H.C., Leung D.Y. Superantigens, conventional antigens and etiology of Kawasaki syndrome. Pediatr Infect Dis J 2000, 19:91-94.
30. Rowley A.H., Baker S.C., Shulman S.T., Rand K.H., Tretiakova M.S., Perlman E.J., et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. J Infect Dis 2011, 203:1021-1030.
31. Wang Y., Wang W., Gong F., Fu S., Zhang Q., Hu J., et al. Evaluation of intravenous immunoglobulin resistance and coronary artery lesions in relation to Th1/Th2 cytokine profiles in patients with Kawasaki disease. Arthritis Rheum 2013, 65:805-814.
32. Jia S., Li C., Wang G., Yang J., Zu Y. The T helper type 17/regulatory T cell imbalance in patients with acute Kawasaki disease. Clin Exp Immunol 2010, 162:131-137.
33. Crome S.Q., Wang A.Y., Levings M.K. Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol 2010, 159:109-119.
34. Afzali B., Mitchell P., Lechler R.I., John S., Lombardi G. Translational mini-review series on Th17 cells: induction of interleukin-17 production by regulatory T cells. Clin Exp Immunol 2010, 159:120-130.
35. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012, 51:v3-v11.
36. Takahashi K., Oharaseki T., Wakayama M., Yokouchi Y., Naoe S., Murata H. Histopathological features of murine systemic vasculitis caused by Candida albicans extract: an animal model of Kawasaki disease. Inflamm Res 2004, 53:72-74.
37. Miura N.N., Komai M., Adachi Y., Osada N., Kameoka Y., Suzuki K., et al. IL-10 is a negative regulatory factor of CAWS-vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice. J Immunol 2009, 183:3417-3424.
38. Oharaseki T., Kameoka Y., Kura F., Persad A.S., Suzuki K., Naoe S. Susceptibility loci to coronary arteritis in animal model of Kawasaki disease induced with Candida albicans-derived substances. Microbiol Immunol 2005, 49:181-189.
39. Oharaseki T., Yokouchi Y., Yamada H., Mamada H., Muto S., Sadamoto K., et al. The role of TNF-a in a murine model of Kawasaki disease arteritis induced with a Candida albicans cell wall polysaccharide. Mod Rheumatol 2014, 24:120-128.
40. Cimaz R., Falcini F. An update on Kawasaki disease. Autoimmun Rev 2003, 2:258-263.
41. Kato T., Numaguchi A., Ando H., Yasui M., Kishimoto Y., Yasuda K., et al. Coronary arterial ectasia in a 2-year-old boy showing two symptoms of Kawasaki disease without manifesting fever. Rheumatol Int 2012, 32:1101-1103.
42. Uehara R., Igarashi H., Yashiro M., Nakamura Y., Yanagawa H. Kawasaki disease patients with redness or crust formation at the Bacille Calmette-Guerin inoculation site. Pediatr Infect Dis J 2010, 29:430-433.
43. Galeotti C., Bayry J., Kone-Paut I., Kaveri S.V. Kawasaki disease: aetiopathogenesis and therapeutic utility of intravenous immunoglobulin. Autoimmun Rev 2010, 9:441-448.
44. Smith L.B., Newburger J.W., Burns J.C. Kawasaki syndrome and the eye. Pediatr Infect Dis J 1989, 8:116-118.
45. Alexoudi I., Kanakis M., Kapsimali V., Vaiopoulos G. Kawasaki disease: current aspects on aetiopathogenesis and therapeutic management. Autoimmun Rev 2011, 10:544-547.
46. Yeter D., Deth R. ITPKC susceptibility in Kawasaki syndrome as a sensitizing factor for autoimmunity and coronary arterial wall relaxation induced by thimerosal's effects on calcium signaling via IP3. Autoimmun Rev 2012, 11:903-908.
47. Zulian F., Falcini F., Zancan L., Martini G., Secchieri S., Luzzatto C., et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr 2003, 142:731-735.
48. Burgner D., Festa M., Isaacs D. Delayed diagnosis of Kawasaki disease presenting with massive lymphadenopathy and airway obstruction. BMJ 1996, 312:1471-1472.
49. Husain E., Hoque E. Meningoencephalitis as a presentation of Kawasaki disease. J Child Neurol 2006, 21:1080-1081.
50. Farvardin M., Kashef S., Aleyasin S., Nabavizadeh S.H., Sajjadi M., Safari M. Sudden unilateral blindness in a girl with Kawasaki disease. J Pediatr Ophthalmol Strabismus 2007, 44:303-304.
51. Knott P.D., Orloff L.A., Harris J.P., Novak R.E., Burns J.C. Sensorineural hearing loss and Kawasaki disease: a prospective study. Am J Otolaryngol 2001, 22:343-348.
52. Wright H., Waddington C., Geddes J., Newburger J.W., Burgner D. Facial nerve palsy complicating Kawasaki disease. Pediatrics 2008, 122:783-785.
53. Naoe S., Takahashi K., Masuda H., Tanaka N. Kawasaki disease. With particular emphasis on arterial lesions. Acta Pathol Jpn 1991, 41:785.
54. Brown T.J., Crawford S.E., Cornwall M.L., Garcia F., Shulman S.T., Rowley A.H. CDS T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001, 184:940.
55. Yanagihara R., Todd J.K. Acute febrile mucocutaneous lymph node syndrome. Am J Dis Child 1980, 134:603.
56. Binstadt B.A., Levine J.C., Nigrovic P.A., Gauvreau K., Dedeoglu F., Fuhlbrigge R.C. Coronary artery dilation among patients presenting with systemic-onset juvenile idiopathic arthritis. Pediatrics 2005, 116:e89-e93.
57. Kato H., Ichinose E., Yoshioka F., Takechi T., Matsunaga S., Suzuki K., et al. Fate of coronary aneurysms in Kawasaki disease: serial coronary angiography and long-term follow-up study. Am J Cardiol 1982, 49:1758-1766.
58. Nakamura Y., Aso E., Yashiro M., Uehara R., Watanabe M., Tajimi M., et al. Mortality among persons with a history of Kawasaki disease in Japan: can pediatricians safely discontinue follow-up of children with a history of the disease but without cardiac sequelae?. Acta Paediatr 2005, 94:429-434.
59. Senzaki H. Long-term outcome of Kawasaki disease. Circulation 2008, 118:2763-2772.
60. Samada K., Shiraishi H., Sato A., Momoi M.Y. Grown-up Kawasaki disease patients who have giant coronary aneurysms. World J Pediatr 2010, 6:38-42.
61. Newburger J.W., Takahashi M., Beiser A.S., Burns J.C., Bastian J., Chung K.J., et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991, 324:1633-1639.
62. Manlhiot C., Yeung R.S., Chahal N., McCrindle B.W. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease. Pediatr Allergy Immunol 2010, 21:515-521.
63. Freeman A.F., Shulman S.T. Refractory Kawasaki disease. Pediatr Infect Dis J 2004, 23:463-464.
64. Baumer J.H., Love S.J., Gupta A., Haines L.C., Maconochie I., Dua J.S. Salicylate for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev 2006, 4:CD004175.
65. Saadoun D., Bodaghi B., Bienvenu B., Wechsler B., Sene D., Trad S., et al. Biotherapies in inflammatory ocular disorders: interferons, immunoglobulins, monoclonal antibodies. Autoimmun Rev 2013, 12:774-783.
66. Suda K., Kudo Y., Higaki T., Nomura Y., Miura M., Matsumura M., et al. Multicenter and retrospective case study of warfarin and aspirin combination therapy in patients with giant coronary aneurysms caused by Kawasaki disease. Circ J 2009, 73:1319-1323.
67. Zhu B.H., Lv H.T., Sun L., Zhang J.M., Cao L., Jia H.L., et al. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease. Eur J Pediatr 2012, 171:571-578.
68. Newburger J.W., Sleeper L.A., McCrindle B.W., Minich L.L., Gersony W., Vetter V.L., et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007, 356:663-675.
69. Curtis N. Prednisolone added to intravenous immunoglobulin treatment improves outcome in children with severe Kawasaki disease. Arch Dis Child Educ Pract Ed 2013, 98:77-78.
70. Maury C.P., Salo E., Pelkonen P. Elevated circulating tumor necrosis factor-alpha in patients with Kawasaki disease. J Lab Clin Med 1989, 113:651-654.
71. Hirono K., Kemmotsu Y., Wittkowski H., Foell D., Saito K., Ibuki K., et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009, 65:696-701.
72. Burns J.C., Best B.M., Mejias A., Mahony L., Fixler D.E., Jafri H.S., et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008, 153:833-838.
73. Song M.S., Lee S.B., Sohn S., Oh J.H., Yoon K.L., Han J.W., et al. Infliximab treatment for refractory Kawasaki disease in Korean children. Korean Circ J 2010, 40:334-338.
74. Choueiter N.F., Olson A.K., Shen D.D., Portman M.A. Prospective open-label trial of etanercept as adjunctive therapy for Kawasaki disease. J Pediatr 2010, 157:960-966.